#031: May 10th, 2021 - Longevity Marketcap Telemetry
Michael Greve's €300M commitment. Dyno / Stealth / FOXO. Thoughts on what the aging field needs.
Last Week in Longevity
Capital Raise Radar
New Companies on Longevity List
Thoughts on what the aging field needs
*Disclaimer: None of this should be taken as financial advice. It is for educational purposes only.
Mission: To grow a wave of passionate people building, funding, and championing technologies that extend healthy human lifespan.
The Longevity Biotech Show is officially a podcast! Check us out on Spotify. Coming soon to Apple Podcasts, pending approval.
forum.longevitybase.org - I’m rolling out a “StackExchange / Quora” for aging biology / longevity biotech. It’s in open beta right now. Feel free to sign up and try it out. Email me if you would like to become a moderator or if you have some suggestions.
For academics, independent researchers, biotech founders, and scientific-minded enthusiasts.
Ask questions, get answers → builds a searchable longevity research knowledge base.
Every Friday @ 12PM - 5PM EDT. Longevity Virtual Coworking. If you are working on longevity or thinking about getting into the longevity industry, please join me for an experimental virtual longevity coworking space using the Pluto.Video web app. (No sign-up required.)
Bring something to work on.
Feel free to ask questions.
Help out. Connect.
I plan on holding this weekly. It’s free. (Room Link)
The 1% Bet for Longevity-- a website initiative. 36 people have now signed up for the 1% Bet for Longevity Pledge. My goal is to get to 50,000 people and at least 100 companies to pledge 1% of their resources towards funding longevity companies and research by the end of the year.
📝 Last Week in Longevity
Michael Greve announces 300M EUR to fund rejuvenation biotech startups. Michael Greve is the founder of Kizoo Technology Capital and the non-profit Forever Healthy Foundation. Last week Greve announced an additional 300M EUR to fund longevity biotechnology startups through Kizoo.
This is BIG news. To put the announcement into perspective, an average-sized longevity biotech seed round is around $5M, according to the longevitylist.com database. Greve’s capital can therefore seed an additional ~70 longevity startups on top of the 115 longevity startups on Longevity List. Note that the announced funding doesn’t account for the amount of external co-investment that will inevitably follow on, which Greve estimates could result in an extra 3 - 4x in capital.
I believe that this 300M EUR is just the beginning of a golden age for longevity biotech startup funding. Of the top 200 billionaires on Forbe’s list, only 10 are below the age of 40. And no matter how many billions of dollars they might have, once you pass the age of 50 you cease being a billionaire of seconds (at rough current life expectancy estimates).
Michael Greve is an entrepreneur known for co-founding WEB.de, a German web portal company. Greve also founded the Forever Healthy Foundation, which puts on the Undoing Aging conference every year, and Kizoo Technology Capital. Kizoo invests in a number of longevity biotech startups including Elastrin, Cellvie, Lysoclear, Turn Bio, Maia Biotechnology, Lift Biosciences, Underdog Pharmaceuticals, Elevian, Revel Pharmaceuticals, Oisin Biotechnologies, FoxBio, and Antoxorene.
Dyno Therapeutics raises $100M Series A led by a16z. Gene therapy vector engineering is heating up. Two weeks ago Capsida announced a $140M in funding, including a deal with pharma giant AbbVie. Last week Dyno Therapeutics, an AAV capsid engineering startup co-founded by George Church, announced a $100M Series A. Investors in the round included a16z, Lux Capital, Polaris Ventures, and CRV.
Dyno Therapeutics’s platform uses high-throughput generation of capsids through DNA library synthesis and artificial intelligence to optimize the design (safety, targeting, efficiency, manufacturability). Last February the company published a paper in Nature Biotechnology that showed their platform was able to generate viable capsids at a rate 60x+ higher than traditional random mutagenesis approaches.
Gene therapies have mostly been used to treat rare monogenic diseases presently. But the power of a general gene therapy platform that can deliver any gene with precise targeting and timing will be important for longevity therapeutics. Companies such as Gordian Biotechnology, Rejuvenate Bio, and Oisin Biotechnologies are all pursuing gene therapies to target aging. A controversial anti-aging gene therapy for dementia is already being trialed in humans in Mexico by BioViva / Liz Parrish.
FOXO Technologies acquires exclusive license for GrimAge and PhenoAge epigenetic clocks. FOXO Technologies is a startup that is commercializing epigenetic clocks by offering testing services for researchers and also offering a new kind of epigenetic clock-based life insurance. The company announced it had obtained an exclusive license for PhenoAge and GrimAge DNA methylation clocks from UCLA. Both “biological clocks” were developed in part by Steve Horvath, a professor at UCLA who first discovered that DNA methylation patterns could be used to predict age.
PhenoAge is a predictor of aging outcomes including healthspan, Alzheimer’s disease, and heart disease. It was developed by training DNA methylation data to predict phenotypic measures of aging derived from clinical measures (blood biomarkers of inflammation, liver/kidney/immune system function).
GrimAge is a significant epigenetic-based predictor of mortality (i.e time to death). It was trained using DNA methylation data to create surrogate predictors of seven different blood plasma proteins along with the number of smoke-pack years.
Epigenetic clocks are a promising tool for research, therapeutics translation, and potentially clinical trials. Horvath and others have created a non-profit organization, the Clock Foundation, in order to advance the use of epigenetic clocks as surrogate endpoints in anti-aging clinical trials.
Stealth BioTherapeutics (NASDAQ:MITO) post-hoc analysis data for Dry AMD Phase 1 trial. Stock goes wild. Stealth BioTherapeutics is a clinical-stage biotech company that develops peptide therapies targeting the mitochondria. Their core asset is elamipretide, a peptide that stabilizes a mitochondrial membrane lipid called cardiolipin. Last week Stealth announced results from a post-hoc analysis of their Phase 1 trial for dry age-related macular degeneration, showing a correlation between improvements in low-light eyesight and the changes in the ellipsoid zone of the retina, a mitochondria-rich region in photoreceptors. Though the data was only post-hoc and suggestive, Stealth’s stock surged 35% on the news, possibly in the hopes that data bodes well for their ongoing Phase 2 Dry AMD trial.
📅 Longevity Futures
Join us for a conversation with Marco Quarta, a researcher at Stanford University and co-founder of Rubedo Life Sciences, a biotech company developing targeted senolytics. Please note the different time (8PM ET).
Stick around at the end of each show for a casual “after-party” longevity biotech chat/networking.
Sign up for reminders via Google Calendar. Click this link for email reminders for all future Longevity Biotech Show events.
Wednesday, May 12th, 2021 @ 11AM EDT. Aubrey de Grey and S. Jay Olshansky Longevity Webinar - Healthspan Show. Free online talk. Aubrey de Grey is the founder of SENS Research Foundation and Jay Olshansky is a professor of epidemiology at the University of Illinois Chicago.
Thursday May 13th, 2021 @ 10AM PDT / 1PM EDT Aubrey de Grey + Vitalik Buterin + VitaDAO Live AMA. Live on YouTube. Post your questions on this Twitter thread. VitaDAO is a decentralized organization that seeks to invest in longevity research projects and provide a mechanism for ownership in the resulting IP -- all on the Ethereum blockchain.
Wednesday, May 26th, 2021 @ 7AM EDT. João Pedro de Magalhães Integrative Genomics of Aging Seminar. Zoom.
Summer Aging Seminars at Loyal. Celine Halioua, the founder of dog life-extension startup Loyal, is putting on aging science seminars this summer at their headquarters in San Francisco. Register to join.
August 31st, 2021 - September 3, 2021. Aging Research and Drug Discovery Conference 2021.Online. An incredible lineup of speakers including: David Sinclair, Alex Zhavoronkov, Thomas Rando, Peter de Keizer, Collin Ewald, Kristen Fortney, Nir Barzilai, Brian Kennedy, Manuel Serrano, Vera Gorbunova, and many others.
Know of any interesting longevity talks, meetings, or events? Please email me.
📡 Capital Raise Radar
I do not endorse or have affiliations with any of the companies listed below. This is not an offer to buy or sell securities. This is for informational purposes only. If you have intel on any other longevity companies currently raising please email me. It’s free.
Developing compounds that target mitochondrial dysfunction to reverse aging. Includes natural compound cosmeceutical for skin aging and hair loss. Also developing pharmaceuticals for prostate / ovarian conditions.
Team: Keshav Singh (University of Alabama), Greg Schmergel (Nantero)
Developing recombinant alpha-2-macroglobulin (A2M) protein to treat osteoarthritis. Also developed a diagnostic biomarker test for osteoarthritis.
Team: Gaetano Scuderi, Antonio Carvalho, Joey Bose, Lewis Hanna
Crowdfunding on SeedInvest. Open to all investors, even retail.
High-throughput phenotypic screen platform to discover anti-aging drugs.
Team includes academics from the Buck Institute: Simon Melov, Mark Lucanic, Gordon Lithgow.
Crowdfunding on WeFunder. Open to all investors, even retail.
Already raised $2.1M on a $15M valuation.
Senolytic gene therapy using a lipid-protein nanoparticle delivery vehicle. Kills cells that express the p16 gene -- a marker of senescent cells. Inducible apoptosis gene with a p16 promoter triggered by a chemical dimerizer.
Team: Matthew Scholz (Immusoft), Gary Hudson.
Seed round. Accredited investors only. $50K minimum check size.
Makers of Rejuvant Life Tabs, a calcium alpha-ketoglutarate supplement (CaAKG). Alpha-ketoglutarate is a key molecule in the Krebs cycle. Brian Kennedy (former head of Buck Institute, now at the National University of Singapore) is the CSO of this company.
CaAKG supplementation reduces frailty and extends maximum lifespan of female mice by 20%. (Shahmirzhadi et al 2020)
Currently “soft-closed” $5.5 M for their Series B. Looking to raise up to $15 M total.
Small molecule drugs that enhance cognition and reduce neuron excitability to treat neurodegenerative and CNS conditions (including anxiety and depression).
Targets the nitric oxide and CREB pathways.
Same team that built Cardioxyl ($2B exit to Bristol Myers Squib)
Mitochondrial uncoupler drug to burn fat through natural body heat production.
Targeting obesity, type 2 diabetes, fatty liver disease, PCOS.
Pro longevity: Exercise mimetic, increases mitochondrial biogenesis, etc
Y Combinator-backed company.
Team: Jonah Sinick, Yuriy Kirichok, Michael Grabe, Liliya Gabelev, David Segura
+ see all (click on “Capital Raise Radar”)
✨ Featured Longevity Jobs
Looking for jobs, companies, or investors in the longevity biotechnology industry? Check out my website LongevityList.com.
C elegans Research Scientist// Magnitude Biosciences // Durham, England
Research Associate // SENS Research Foundation // Mountain View, California
Research Associate Immunonology // SENS Research Foundation // Mountain View, California
Senior Scientist - Applications// Turn Bio // Mountain View, California
Senior Scientist - Technology // Turn Bio // Mountain View, California
Senior Scientist/Director - Chemist // Turn Bio // Mountain View, California
Senior Scientist/Director - Formulation // Turn Bio // Mountain View, California
Engineering Intern // Cellvie // Matzingen, Switzerland
Senior Scientist, Biochemist // Cellvie // Matzingen, Switzerland
Medical Analyst for Rejuvenation Therapies // Forever Healthy // Karlsruhe, Germany or Remote
Analyst for Functional and Preventive Medicine // Forever Healthy // Karlsruhe, Germany or Remote
Scientific Spokesperson // Forever Healthy // Karlsruhe, Germany or Remote
Head of Global Communications // Forever Healthy // Karlsruhe, Germany or Remote
Head of Consumer // Loyal // San Francisco, Remote
Computational Bio Internship // Loyal // San Francisco? / Remote?
Epigenetics / Reprogramming Postdoc// Morgan Levine Lab (Yale) // Yale
SPAC Investment Professional // Maximon // Zug, Switzerland
Associate Director/Director of In Vivo Biology/Pharmacology// BioAge Labs // Richmond, CA, USA
+ more longevity jobs
If you are hiring, email me a link to your job postings and I will post them on longevitylist.com (it’s free).
➕ New Companies on Longevity List
Retro Biosciences: A new stealth longevity therapeutics by Joe Betts-LaCroix. The company intends to target multiple age-related diseases with a single therapy. Joe Betts-LaCroix is a biophysicist and entrepreneur. He was co-founder of Vium/Mousera and an investor in Recursion Pharma, Spring Discovery, and StemCentrx.
Lift Biosciences: A pan-cancer cell therapy startup developing allogeneic off-the-shelf neutrophils derived from exceptional cancer-resistant individuals. Investors include Jonathan Milner and Kizoo Technology Capital.
Thoughts on “What the Aging Field Needs”
More teams taking on regulatory risk
Longevity companies are aiming to trial drugs for specific proxy diseases -- not aging. This introduces the risk of false fails -- where the drug actually works for aging but fails for other reasons related to the chosen proxy indication.
One solution could be to find ways to do better preventative medicine trials in age-related diseases. It may be that reversing a disease of aging with advanced pathology might be much harder for the first aging drugs we develop, even if the drug being tested works for aging in general.
More translational aging companies
Nobody is really attempting aging trials.
Aging biomarkers are being discussed as a surrogate endpoint but I have yet to see a public roadmap on how such a biomarker will be approved by the FDA.
More sustainable business models
Aging startups need to break free from relying on cash from risk-averse big pharma
Most biotechs end up selling to big pharma or requiring big pharma for cash. But big pharma companies are not very interested in aging -- AbbVie perhaps is an exception.
Aging (and perhaps gene therapy) could be the next paradigm shift in medical biotechnology that allows for new biotech companies to displace big pharma incumbents.
Ideally, we want aging companies to become self-sustaining, reinvesting their profits back into new R&D.
More investors bullish on aging
High quality bar, long time horizons, significant resources. Pick two.
Longevity biotech is still a very young industry.
Which one of the three (high quality bar, long time horizon, significant resources) is most easily rectified if lacking? Probably “high quality bar”. Increasing investor sophistication (either through learning or recruitment of suitable advisors) is much easier than trying to change an investor’s time horizon or increasing their wealth.
So who belongs to this glorious demographic of well-capitalized + long time horizon investors that lack aging biotech sophistication? Young crypto millionaires and billionaires. They are not in immediate need of anti-aging therapies but have more money than they know what to do with it. Vehicles like VitaDAO might be effective ways to capture some of this crypto wealth investment.
More (strategic) conservatism
Aging drugs are not about immortality or radical life extension...yet. This is something to debate later.
Ideas of longevity escape velocity and immortality tend to be too extreme for the general public. It’s much easier to digest longevity as medicine that happens to prevent diseases of aging and reduce all-cause mortality.
I’m divided on whether we actually need a large percentage of the public to get on board the longevity train before the first anti-aging drug is demonstrated. However, a large political mandate to approve anti-aging drugs would definitely help pressure the FDA.
More new ideas
An interdisciplinary approach
Sometimes it takes fresh ideas from outside your niche (aging biology) to make progress.
Aubrey de Grey wrote about how knowledge of soil bacteria held a potential key to degrading lipofuscin in his book Ending Aging. A startup called Lysoclear is attempting this approach.
Cellino, a stem cell startup, uses AI, robotics, and lasers to manipulate stem cells in manufacturing.
Now please enjoy this talk on the physics of aging:
Some of my projects, resources, and ways to support my mission. More projects coming…
Longevity List - Find jobs, companies, and investors in the longevity industry. Email me if you want to add your job or company to the list. It’s free.
Longevity List Database- A handy Airtable base covering people, companies, trials, academic labs, and a list of longevity companies that are presently raising capital.
LMC Clinical Trial Tracker- Longevity therapeutics in clinical trials. Completion calendar useful for investors who want to time data readout catalysts.
LongevityMarketcap.com- The main page tracks prices of publicly traded longevity stocks.
Longevity Biotech Show - Official website of the Clubhouse show / podcast. We interview the people building, funding, and championing technologies that extend healthy human lifespan. On Clubhouse / Spotify podcasts.
The One Percent Bet for Longevity Pledge - An initiative to get individuals and corporations to pledge at least 1% of their resources to fund longevity companies and research.
LongevityBase.org - An open-source volunteer initiative to itemize every instance of modulation of biological aging in the scientific literature.
forum.longevitybase.org - An open question and answer system for aging biology and longevity biotechnology.
Patreon - For people who want to support my work and mission. Premium tiers include access to my private Telegram group for behind-the-scenes thoughts and network.
Twitter- Random thoughts and link shares. My DMs are open.
A special thanks to my Patreon supporters who have joined forces with me to undertake this mission.